Insomnia
therapeutics Market By Drug Class (Nonbenzodiazepines, Benzodiazepines and
Others) and By Distribution Channel (Retail & Hospital Pharmacies and
Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Insomnia is a common type of
sleep disorder and frequently co-morbid with mental or psychiatric illness.
Consistent risk factors for insomnia are age, and stress associated with job,
family, financial, and medical conditions. Increase in consumption of alcohol,
caffeine, nicotine could also lead to insomnia. Depending on the duration,
insomnia is categorized into transient and chronic insomnia. Transient insomnia
last for a single night to few weeks or months and is an adaptive response to
the above mentioned challenges. Chronic insomnia is more complex resulting from
combination of factors mentioned above and lasts for longer period of time.
Insomnia is normally treated with prescription medication or over the counter
sleep aid such as natrol melatonin and unisom sleep gel help people to fall
asleep with minimum side effects. According to a study by University of Laval,
2011, about 40 % of the adult Canadian are experiencing one or more symptoms of
insomnia. Further, a latest research reported in Nature, 2017, stated that
insomnia increases the risk in women to deliver premature babies by 30%.
Increase in incidence of insomnia across the globe will propel the insomnia
therapeutics market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/958
New improved medication with
lesser side effects will drive the insomnia therapeutics market growth globally
Benzodiazepines (BZP) such as
temazepam and diazepam are the commonly prescribed medication for insomnia.
Though these medications are effective, prolonged use of these drugs may cause
cognitive impairment, dependency and addiction. The launch of novel drugs such
as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7
countries in the insomnia therapeutics and is expected market over the forecast
period.
Intermezzo (2014), are used in
small doses and administered under the tongue for faster absorption. Tesimelton
approved by FDA in 2014 is the only drug approved by FDA for Non-24-Hour
Sleep-Wake Rhythm Disorder and it lacks abuse potential. These products are
expected to drive the insomnia therapeutics market over the forecast period.
Increasing awareness and
treatment seeking rates for insomnia are expected to further contribute to the
growth of the market. However, the loss of exclusivity of the drugs led the
market more genericized, creating a competitive environment for new entrants.
For instance, non-benzodiazepines and low dose sedating anti-depressants, still
considered as a first line of medication for the insomnia, are facing stiff
competition from the generics.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/insomnia-therapeutics-market-958
According to a report by Sleep
Research Society, 2012, 20% of the general adult population in Canada and U.S
is suffering from insomnia and this number is expected to increase in the near
future. Problems like daytime sleepiness, and fatigue is affecting larger
number of population and imposing a considerable burden on these regions. These
factors all together will trigger the total insomnia therapeutics market demand
in the future period.
Devices would have a negative
impact on the global insomnia therapeutics market
Rapid entry of new players and
new devices for insomnia will boost the market over the forecast period. FDA
approved new device Cerêve Sleep System for insomnia in 2016 this device is
used to reduce latency to stage 1 and stage 2 sleep by keeping the forehead
cool. Major players in insomnia therapeutics market are GlaxoSmithKline plc,
UCB Group, Otsuka Holdings Co., Ligand Pharmaceuticals Incorporated, Axxonis
Pharma AG, Kyowa Hakko Kirin Co. Ltd., National Institute of Neurological
Disorders and Stroke, Jazz Pharmaceuticals, Inc. Ltd., Omeros Corporation and
Manhattan Pharmaceuticals, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/958
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment